Skip to content
BHP

2026-02-11 · Research summary

BPC-157 in tendon healing — what the 2024 evidence base shows

Across more than two dozen rodent studies, BPC-157 has consistently improved biomechanical recovery, collagen organisation, and tenocyte migration after experimental tendon injury. Translation to human work remains unproven.

What we know

Independent rodent studies of Achilles transection, rotator-cuff injury, and medial collateral ligament injury have reported faster recovery of biomechanical properties under BPC-157 treatment compared with saline controls. Mechanistic studies attribute this to growth-hormone-receptor upregulation in tenocytes and angiogenic effects on the peritendinous vascular network.

What we don't know

There are no published human controlled trials. The optimal dose, route, duration, and timing relative to injury are not established. Long-term safety, immunogenicity, and effects in degenerative (rather than acute) tendon disease are unstudied.

Implications for research design

Future studies that include longer follow-up, force-loading rehabilitation arms, and quantitative collagen-isoform analysis would help distinguish true tissue regeneration from accelerated, mechanically inferior scar formation.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.